Every material Form 8-K Celularity Inc has filed with the SEC since September 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Celularity Inc. announced on October 29, 2026, an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to make U.S.-based peptide active pharmaceutical ingredients under Vesalius's Peptual brand at Celularity's New Jersey facility. The filing does not disclose any financial terms, revenue expectations or contract value, so its effect on Celularity's financial results cannot be assessed from the filing.
Announced October 29, 2026; press release filed as Exhibit 99.1 to Form 8-K
Celularity performs downstream purification, processing, analytical testing and manufacturing at its Florham Park, New Jersey facility
Supply to U.S. compounding pharmacies is conditional on future FDA action following Pharmacy Compounding Advisory Committee recommendations
The collaboration will not involve GLP-1 receptor agonists or other weight-loss peptides
Celularity Inc. appointed Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors, with his term to start after a Rule 14f-1 information statement waiting period. Diane Parks has notified the company she will resign from the Board as of that same effective time, and the filing says her decision was not due to any disagreement with the company.
Naveen Jain was designated under board designation rights tied to the September 2026 financing disclosed in an 8-K filed September 28, 2026.
Diane Parks will resign from the Board effective at the same time Jain's term begins.
Jain has not been appointed to any Board committee initially and will receive the standard non-employee director compensation.
The company expects to announce a fifth director shortly.
On September 24, 2026, Celularity closed the initial phase of a financing agreement signed September 23 for up to $25.0 million of senior secured convertible notes, raising $11.01 million in gross proceeds with warrants for about 4,037,000 shares. The filing also shows a September 18 settlement with Helena in which 2,000,000 additional shares were issued, and the notes and warrants could add substantial share dilution for existing holders.
Initial closing on September 24, 2026: $11.01 million in notes, convertible at $1.50 per share into about 7,340,000 shares
Warrants for about 4,037,000 shares, exercisable at $1.50 per share for five years
Notes bear 10% interest, mature 24 months after issue, and are secured by substantially all company and subsidiary assets
Helena settlement dated September 18, 2026: 700,000 shares issued on conversion of $1.197 million at $1.71 per share, plus 2,000,000 additional shares
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Celularity Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →